Free Trial
OTCMKTS:PMCBD

PharmaCyte Biotech (PMCBD) Stock Price, News & Analysis

PharmaCyte Biotech logo
$6.68 -0.96 (-12.54%)
As of 11/13/2026

About PharmaCyte Biotech Stock (OTCMKTS:PMCBD)

Advanced

Key Stats

Today's Range
$6.50
▼
$8.17
50-Day Range
$0.30
▼
$0.49
52-Week Range
$5.56
▼
$55.50
Volume
126,655 shs
Average Volume
8,831 shs
Market Capitalization
$11.16 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

PharmaCyte Biotech, Inc. is a clinical-stage biotechnology company focused on developing therapies for cancer and other serious diseases. The company’s primary program has centered on locally advanced pancreatic cancer, an aggressive disease with limited treatment options.

PharmaCyte’s investigational approach uses its Cell-in-a-Box technology, which involves encapsulating genetically engineered cells in proprietary cellulose-based capsules. These cells are designed to produce an enzyme that converts the chemotherapy prodrug ifosfamide into its active form near the tumor, with the goal of concentrating treatment at the disease site while reducing exposure to healthy tissue.

PharmaCyte Biotech does not have commercially marketed products and has focused primarily on research, clinical development, regulatory activities and potential partnerships. The company’s programs have been developed for international clinical and regulatory markets, although their availability remains dependent on successful clinical trials and regulatory approval.

AI Generated. May Contain Errors.

Receive PMCBD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for PharmaCyte Biotech and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

PMCBD Stock News Headlines

PharmaCyte Biotech Reports Strong Cash and Asset Position
PharmaCyte Biotech, Inc. Announces Reverse Stock Split
I'm handing you this stock today
Elon doesn't own the chip inside his Teslas or Starlink dishes. He licenses it from one little known public company. Now he's planning 1,000,000 AI satellites in orbit, and every one could pay this company a royalty. Analyst Dylan says the window to get in closes around December 8th, before new money floods into the buildout.tc pixel
PharmaCyte Biotech Inc.
See More Headlines

PMCBD Stock Analysis - Frequently Asked Questions

PharmaCyte Biotech's stock was trading at $0.7101 at the start of the year. Since then, PMCBD stock has increased by 840.7% and is now trading at $6.68.

Shares of PMCBD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Industry
Biological Products, Except Diagnostic
Sub-Industry
N/A
Current Symbol
OTCMKTS:PMCBD
CIK
N/A
Fax
N/A
Employees
N/A
Year Founded
1996

Profitability

EPS (Trailing Twelve Months)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$3.83 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-49.09%
Return on Assets
-43.39%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
4.90
Quick Ratio
4.90

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
N/A
Price / Book
N/A

Miscellaneous

Outstanding Shares
1,671,000
Free Float
N/A
Market Cap
$11.16 million
Optionable
Not Optionable
Beta
0.27

Social Links

7 Stocks to Buy Before the Robotics Revolution Cover

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

This page (OTCMKTS:PMCBD) was last updated on 11/13/2026 by MarketBeat.com Staff.
From Our Partners